Researchers outlined a modular, dose-tunable viral vector architecture for sequential neuroprotective therapies in complex retinal diseases. The proposed system is designed to let clinicians adjust treatment dosing and timing across stages, aiming to reduce the rigidity of one-size-fits-all dosing while maintaining a framework that can support combination strategies within inherited retinal disease programs.
Get the Daily Brief